⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NGNE News
Neurogene, Inc. Common Stock
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Form 8-K
sec.gov
NGNE
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
NGNE
Neurogene to Participate in Upcoming Investor Conferences
businesswire.com
NGNE
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
NGNE
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
businesswire.com
NGNE
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
businesswire.com
NGNE
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com
NGNE